Filtered By:
Specialty: Cancer & Oncology
Cancer: Colon Cancer
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 252 results found since Jan 2013.
Abstract 3903: A sub-set of DCLK1+ve colon cancer stem cells (CSCs) survive curcumin induced autophagy, while co-treatment with curcumin +DCLK1-siRNA eliminates CSCs: Role of long and short isofoms of DCLK1
Conclusion. Our studies strongly suggest that, 1) DCLK1 represents a functional protein for colon cancers, 2) combination of curcumin+DCLK1-siRNA may target and eradicate colon cancer stem cells., and 3) identifying small molecules that inhibit expression of S-isoform may allow to specifically target cancer stem cells, while sparing normal stem cells for cancer treatment purposes.
This work was supported by NIH Granst to PS (R01CA09795909 and RO1CA0975909-S1).
Citation Format: Shubhashish Sarkar, Malaney O'Connell, Carla, Kantara, Pomila Singh. A sub-set of DCLK1+ve colon cancer stem cells (CSCs) survive curcumin induced a...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Sarkar, S., O'Connell, M., Kantara, C., Singh, P. Tags: Tumor Biology Source Type: research
Abstract 868: Characterization of LASEP3 as a serological and prognostic biomarker and a therapeutic target for lung cancer
This study aims to identify novel biomarkers or therapeutic targets for lung cancers. We used cDNA microarrays for screening genes encoding transmembrane/secretory proteins that are up-regulated in lung cancers. During this process, we identified a secreted protein, LASEP3 (lung cancer-associated serum protein 3) as a candidate. Immunohistochemical staining of LASEP3 showed that LASEP3 expression was observed in 198 (54.8%) of 361 NSCLCs (non-small cell lung cancer) that had undergone curative surgery. High level of LASEP3 expression was associated with poor prognosis for NSCLC patients. (P=0.0183 by log-rank test). Serum ...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Takano, A., Nakamura, Y., Daigo, Y. Tags: Clinical Research (Excluding Clinical Trials) Source Type: research
Abstract 1393: Correlating the expression of protein kinase C isozymes with the transformed phenotype in colorectal cancer
Protein Kinase C (PKC) is a family of serine/threonine kinases that are involved in almost every signal transduction pathway. Their regulation is mediated by several factors and by binding to a group of scaffolding proteins called RACKs (Adams et al. 2011). The development of PKC modulators with anti-cancer therapeutic value is a major target in cancer. However, this task is made difficult because PKC has an important role to play in normal processes and the PKC family consists of at least 12 different isozymes. In colon cancer, there is differential expression of the PKC isozymes, giving the cancer cells a migratory advan...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Dowling, C. M., Hanly, J., Dalton, T., Kiely, P. A. Tags: Molecular and Cellular Biology Source Type: research
Abstract SY43-03: Screening for triple negative breast cancer vulnerabilities
There is no targeted therapy for triple negative breast cancers (TNBC), which have the worst prognosis of human breast cancers. TNBCs are prone to relapse and metastasize after cytotoxic drug treatment. This group of cancers, defined by low or absent expression of estrogen, progesterone and Her2 receptors, are heterogeneous in genetic, epigenetic and phenotypic features, making it difficult to identify specific drug targets suitable for this group of cancers as a whole. About half or more of TNBCs have an epithelial phenotype (classified based on gene expression profiling as basal-like or basal-A) and a large minority of t...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Petrocca, F., Altschuler, G., Tan, S. M., Mendillo, M. L., Yan, H., Jerry, D. J., Kung, A. L., Hide, W., Ince, T. A., Lieberman, J. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 5112: Histone deacetylase and proteasome inhibitors synergistically induce apoptosis in colon cancer, multiple myeloma and CTCL cells through induction of the immediate early genes ATF3 and JUN
Conclusions: This study provides insight into the mechanistic basis by which combination treatment with HDAC and proteasome inhibitors synergistically induces apoptosis in tumour cells.
Citation Format: Janson WT Tse, Anderly C. Chueh, Ian Y. Luk, Fiona Chionh, Yvonne Yeung, Georgia A. Corner, Dominic CH Ng, Hoanh Tran, Amardeep S. Dhillon, John M. Mariadason. Histone deacetylase and proteasome inhibitors synergistically induce apoptosis in colon cancer, multiple myeloma and CTCL cells through induction of the immediate early genes ATF3 and JUN. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Associ...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Tse, J. W., Chueh, A. C., Luk, I. Y., Chionh, F., Yeung, Y., Corner, G. A., Ng, D. C., Tran, H., Dhillon, A. S., Mariadason, J. M. Tags: Molecular and Cellular Biology Source Type: research
Abstract 2730: RNAi knockdown or chemical inhibition of anaphase-promoting complex components is synthetic lethal with HSP90 inhibition
The molecular chaperone heat shock protein 90 (HSP90) maintains the conformation, stability and function of oncogenic client proteins, many of which are mutated or overexpressed. Therefore, HSP90 is an important cancer therapeutic target. To further increase the efficacy of HSP90 inhibitors, combinatorial therapeutic strategies may be beneficial. Here we report an unbiased global screening approach to identify genes that encode potentially druggable proteins that modulate cellular responses to HSP90 inhibition. From the 7,593 genes that were tested, three components of the anaphase-promoting complex (APC/C) were among the ...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Howes, J., Lu, B.-F., Powers, M., Mitsopoulos, C., Al-Lazikani, B., Linardopoulos, S., Clarke, P., Workman, P. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 2003: CPE-delta-N promotes metastasis by regulating Nedd9 and Yap1 expression
We report here that the carboxypeptidase E gene (CPE) is alternatively spliced in human tumors to yield an N-terminal truncated protein (CPE-DELTA-N) that drives metastasis. CPE-DELTA-N mRNA was elevated in human metastatic colon, breast and HCC cell lines. Suppression of CPE-DELTA-N expression in these cell lines by si-RNA significantly inhibited their growth migration and invasion. To confirm these observations in vivo, an orthotopic nude mouse model was established. The mice implanted with a tumor derived from HCC cells transfected with si- CPE-DELTA-N RNA in the liver did not show tumor growth or metastasis, compared t...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Murthy, S. R. K., Lee, T. K., Cawley, N. X., Hewitt, S. M., Loh, P. Y. Tags: Tumor Biology Source Type: research
Abstract 3537: Suppression of miR-145 by long noncoding RNA RoR in colon cancer
Conclusion: Taken together, these results suggest that lncRNA-RoR plays an oncogene role in colon cancer in part through suppression of the tumor suppressor miR-145. Thus, a better understanding of the p53-RoR-miR-145 regulatory system will provide new insight of colon cancer therapy.
Citation Format: Jianguo Huang, Yin-Yuan Mo. Suppression of miR-145 by long noncoding RNA RoR in colon cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3537. doi:10.1158/1538-7445.AM2014-3537
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Huang, J., Mo, Y.-Y. Tags: Molecular and Cellular Biology Source Type: research
Abstract 4897: Genetic variants and expression of AEG-1 in relation to clinical outcome and radiotherapy response in colorectal cancer patients and cell lines
Background: Colorectal cancer (CRC) is the third most common cancer in men and the second in woman worldwide. The therapy of CRC has been critically improved during the past two decades, but the treatment response varies significantly between different treatments and patients. Therefore it is of need to search for biomarkers for more suitable prognosis and treatment. The aim of this study was to investigate genetic variants of the astrocyte elevated gene-1 (AEG-1), its expression in CRC patient samples and colon cancer cell lines and the potential correlation to clinicopathological variables and treatment response.
Materia...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Gnosa, S., Brodin, V. P., Ticha, I., Adell, G., Arbman, G., Zhang, H., Sun, X.-F. Tags: Tumor Biology Source Type: research
Abstract 1762: Phosphodiesterase 10, a novel target for colorectal cancer therapeutics
Phosphodiesterase 10 (PDE10) is a newly characterized PDE isozyme that is expressed in regions of the brain affecting cognition and psychomotor activity. Inhibitors are currently being developed for the treatment of schizophrenia and Huntington's disease, one of which, Pf-2545920 (MP-10), is in clinical trials. Although PDE10 is not expressed in most peripheral tissues, we recently found high levels in colon tumor cells compared with normal colonocytes and that genetic silencing by siRNA selectively suppressed colon tumor cell growth. These observations suggest that PDE10 may represent a novel anticancer target. Pf-2545920...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Lee, K. J., Li, N., Chen, X., Zhu, B., Yet, L., Piazza, G. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 1773: Phosphodiesterase 10A: A novel target for selective inhibition of colon tumor cell growth and Wnt/{beta}-catenin signaling
The cyclic nucleotide phosphodiesterase10A (PDE10) has been studied as a therapeutic target for certain psychiatric and neurological conditions, although a potential role in tumorigenesis has not been reported. Here we report that PDE10 is elevated in human colon tumor cell lines compared with normal colonocytes. Similarly, PDE10 is elevated in colon tumors from human clinical specimens as well as intestinal tumors from the ApcMin/+ mouse model compared with non-involved tissue or normal intestinal mucosa, respectively. An isozyme and tumor-selective role of PDE10 was evident by the ability of specific inhibitors and siRNA...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Li, N., Lee, K., Xi, Y., Zhu, B., Gary, B. D., Ramirez–Alcantara, V., Gurpinar, E., Canzoneri, J. C., Faȷardo, A., Sigler, S., Piazza, J. T., Chen, X., Andrews, J., Lu, W., Li, Y., Russo, S., Yet, L., Keeton, A. B., Grizzle, W. E., Piazza, G. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 2283: Potent curcumin analog FLLL-12 targets both intrinsic and extrinsic signaling pathways to induce apoptosis in lung cancers
Conclusions: Our results strongly suggest that FLLL-12 is a potent curcumin analog that induces apoptosis of lung cancer cell lines by targeting: (1) intrinsic pathways via transcriptional inhibition of EGFR and AKT and induction of BIM, and (2) extrinsic pathway via induction of DR5. Future in vivo studies using appropriate animal models are warranted for further development of this promising compound for cancer prevention and/or treatment for lung cancer.
(Supported by R03CA171663, P50CA128613 and Robbins Scholar Award of Winship Cancer Institute of Emory University).
Citation Format: A.R.M. Ruhul Amin, Abedul Haque, Moh...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Amin, A. R. M. R., Haque, A., Rahman, M. A., Fuchs, J. R., Chen, Z. G., Shin, D. M. Tags: Molecular and Cellular Biology Source Type: research
Abstract 785: ETS-mediated expression of miR-24 regulates Top1 levels and resistance of prostate cancer cell lines to camptothecin
In this study, we identified one resistance mechanism linked to the regulation of Top1 levels via the overexpression of transcription factors from the ETS family (mainly ERG and ETV1) that is detected in 50-80% of PCa. We first showed that siRNA-mediated transient repression of ERG or ETV1 in ERG-overexpressing VCaP cells and in ETV1-overexpressing LNCaP cells, respectively, resulted in increased cell sensitivity to CPT, confirming the role of these two ETS transcription factors in PCa cell response to Top1 inhibitors. Using the CHiP-Seq database from UCSC, we could identify potential ETS binding domains in the promoter re...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Kayali, S., Roche, E., Montaudon, D., Pourquier, P., Houede, N. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 1044: Pyruvate kinase M2 stimulates the epithelial-mesenchymal transition by genetically controlling E-cadherin expression in colon cancer
In conclusion, our data suggested that PKM2 nuclear function had a crucial role in controlling invasion and metastasis.
Citation Format: Masamitsu Konno, Atsushi Hamabe, Yuichiro Doki, Masaki Mori, Hideshi Ishii. Pyruvate kinase M2 stimulates the epithelial-mesenchymal transition by genetically controlling E-cadherin expression in colon cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1044. doi:10.1158/1538-7445.AM2014-1044
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Konno, M., Hamabe, A., Doki, Y., Mori, M., Ishii, H. Tags: Tumor Biology Source Type: research
Abstract 3355: Inhibiting glyoxylase 1 as a strategy to target highly glycolytic cancer cells
Cancer cells typically display altered glucose metabolism characterized by a preference of aerobic glycolysis (Warburg effect) resulting in higher levels of glycolytic waste including methylglyoxal (MG). GLO1 (Glyoxalase 1) functions in the detoxification of MG: MG reacts with glutathione to form hemithioacetal, which is converted into S-D-Lactoylglutathione by GLO1 and further metabolised into D-lactate by GLO2. When not detoxified, MG acts as a cytotoxic reagent by forming DNA- and protein-adducts (advanced glycation end products = AGEs) that subsequently lead to cell death. Therefore, GLO1 has been discussed as a potent...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Gruenewald, S., Steckel, M., Timmermann, A., Rehwinkel, H., Steigemann, P., Zacharias, S., Walter, A., Bauser, M., Haegebarth, A. Tags: Molecular and Cellular Biology Source Type: research
